Search

Displaying results 3921 - 3930 of 10000 in total
  1. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). … It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV).

  2. Drug

    Epicriptine

    go.drugbank.com/drugs/DB11275
    Approved

    Together with the alpha-dihydroergocryptine, it represents one-third of the ergoloid mesylate mixture. Epicriptine differs from the alpha form on the position of one methyl group.

  3. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    IGN101 is an antibody-based cancer vaccine directed against epithelial cancers. It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  4. Drug

    Benzododecinium

    go.drugbank.com/drugs/DB13282
    Investigational

    Benzododecinium is used as an antiseptic/disinfectant compound. It has been marketed as a tincture for antiseptic product for wounds in the Czech Republic.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Synthetic Conjugated Estrogens, A

    go.drugbank.com/drugs/DB09317
    Approved

    Conjugated Equine Estrogens (CEEs) are derived from the urine of pregnant mares and contain a blend of at least 10 estrogen derivatives. … There is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time.

  6. Drug

    Cat dander extract

    go.drugbank.com/drugs/DB13904
    Approved

    It is used in the diagnosis and treatment (immunotherapy) of patients with a history of allergy to cats. … Cat dander extract can be used in immunotherapy in individuals who cannot avoid exposure to cat allergens to initiate hyposensitization.

  7. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    [L53873,A274363] It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pathways while sparing wild-type epidermal growth factor receptor (EGFR), which … [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain

  8. Drug

    Tilbroquinol

    go.drugbank.com/drugs/DB13222
    Approved

    Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467]. … In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis.

  9. Drug

    Bavituximab

    go.drugbank.com/drugs/DB05136
    Investigational

    It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.

  10. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    secretion which may be involved in the etiology of psoriasis. … Cytochroma anticipates that CTA018 will be more potent than currently marketed vitamin D analogues such as calcitriol and calcipotriol and it is expected to have a greater safety index.